Advancing Sterile Compounding for Healthcare
BMK Pharma is an upcoming 503B outsourcing facility focused on producing high-quality sterile medications to support hospitals, healthcare systems, and clinical providers.
About
BMK Pharma
BMK Pharma is being developed as a 503B outsourcing facility dedicated to producing sterile compounded medications at scale.
Our mission is to support healthcare providers with reliable medication supply, consistent quality, and manufacturing standards aligned with current Good Manufacturing Practices (cGMP).
1
Regulatory Framework
503B outsourcing facilities were established under the Drug Quality and Security Act (DQSA) to strengthen the safety and reliability of compounded medications in the United States.
These facilities are registered with the FDA and operate under strict regulatory oversight.
2
Manufacturing Standards
Unlike traditional compounding pharmacies, 503B facilities follow current Good Manufacturing Practices (cGMP) similar to pharmaceutical manufacturers.
This ensures consistent quality, controlled production environments, and reliable medication supply.
3
Healthcare Supply Support
503B outsourcing facilities produce sterile compounded medications in larger batches to support hospitals, surgical centers, and healthcare providers.
Their role is to help maintain consistent medication availability and support the healthcare supply chain.
.jpg)
At BMK Pharma, we believe that access to high-quality medications is essential for modern healthcare.
Our mission is to support hospitals and healthcare providers through reliable sterile compounding, strict quality standards, and a commitment to patient safety.
Guided by our vision of Building Better Health, we aim to strengthen the healthcare supply chain and improve medication availability.
Dr. Jay Bhaumik
Chairman of BMK Pharma
